Diabetic Retinopathy Clinical Research Network

1. Diabetic Retinopathy Clinical Research Network Dedicated to multicenter clinical research of diabetic retinopathy, macular edema and associated disorders.

2. DRCR Network Overview • Objective: • The development of a collaborative network to facilitate multicenter clinical research on diabetic retinopathy, diabetic macular edema and associated conditions. • Funding: • National Eye Institute-sponsored cooperative agreement initiated September 2002. • Current award through 2013

3. Priority Initiatives • Involvement of community-based practices, as well as “academic” or university-based centers. • Collaborate with industry to facilitate investigations and pursue opportunities otherwise not possible and to do so in a manner consistent with the Network’s dedication to academic integrity and optimal clinical trial performance.

4. Organization: Clinical Sites of the Network • Overall Network Participation (as of 11-4-09) • 222 sites submitted application for Network • 770 total Investigators; 2217 additional personnel • Current Participation • 104 active sites • 68 community based sites • 301 Investigators • 824 additional personnel • 30 States

5. Network Organization:Central Resource Units • Coordinating Center • Adam Glassman, M.S. (Principal Investigator) • Roy Beck, M.D., Ph.D. (Executive Director) • Network Chair • Neil M. Bressler, M.D. (current) • Lloyd Paul Aiello, M.D., Ph.D. (inaugural & past chair) • NEI • Eleanor B. Schron, Ph.D., R.N.

6. Network Organization: DRCR.net Committees • Executive Committee (20 members) • Operations Group (8 members) • Protocol Development Committees (as needed) • Manuscript Writing Committees (as needed) NEI Appointed Committees • Data and Safety Monitoring Committee • External Protocol Review Committee

7. DRCR.net Policies (www.drcr.net) • Publications, Presentations, Publicity • Financial Disclosure • Competing Studies • Industry Collaboration • Confidentiality • Web site use • Site visits/Data audit • Research Integrity/Scientific Fraud

8. How Is a DRCR.net Protocol Created? • Investigators solicited for protocol ideas • Idea submitted to Operations Group (OG), which reviews ideas semiannually • Ideas approved by OG are presented to Investigators at semiannual meetings for buy-in and interest • Executive Committee (EC) prioritizes selected protocols • OG creates Protocol Development Committee • Protocol Development Committee creates protocol • Protocol independently reviewed by NIH-appointed External Protocol Review Committee – advisory to NEI • Protocol approval: Executive Committee; NEI; DSMC; regulatory agencies as needed (e.g., FDA); industry collaborators as needed

9. Current DRCR Network Recruitment (as of November 4, 2009) *Recruitment Ended, ** Protocol Completed

10. Current DRCR Network Recruitment (as of November 4, 2009) ***Recruiting

11. Completed Studies

12. Protocol A: A Pilot Study Comparing Modified-ETDRS and Mild Macular Grid Laser Photocoagulation for DME • Objectives • Hypothesis generation, gathering outcome data, and standardization of data collection methods, testing procedures, and treatment techniques • Major Eligibility Criteria • DME involving or threatening the center of the macula • Best corrected visual acuity >19 letters (≈ 20/400) • No prior focal/grid laser photocoagulation for DME • Enrollment (7/03-11/04) • Total enrolled: 263 subjects/323 eyes at 79 sites

13. Protocol B: A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for DME • Objective • Determine whether IVT injections at doses of 1mg or 4mg produce greater benefit, with an acceptable safety profile, than macular laser photocoagulation. • Major Eligibility Criteria • BCVA ≥ 24 letters (20/320 or better) and ≤ 73 letters (worse than 20/32) • Center-involved DME on clinical exam and OCT • Enrollment (7/04-5/06) • Total enrolled: 693 subjects/840 eyes at 88 sites

14. Protocol C: Temporal Variation in Optical Coherence Tomography Measurements of Retinal Thickening in DME • Objective • To determine the proportion of eyes that demonstrate a potentially meaningful change in central retinal thickening measured on OCT throughout the day. • Major Eligibility Criteria • Definite center involved retinal thickening due to DME • OCT central subfield thickness >=225 microns • Enrollment (10/04-5/05) • Total enrolled: 114 subjects at 25 sites

15. Protocol D: Evaluation of Vitrectomy for DME • Objective • To provide information on outcomes in eyes with DME that undergo vitrectomy • Major Eligibility Criteria • DME with vitrectomy being performed as treatment • Best corrected visual acuity >= 3 letters (≈ 20/800) • Enrollment (5/05 – 1/08) • Total enrolled: 241 subjects at 50 sites • Sample size: 100 subjects

16. Protocol E: A Pilot Study of Peribulbar Triamcinolone Acetonide for DME • Objective • To determine whether posterior and anterior peribulbar injections of triamcinolone acetonide produce greater benefit, with an acceptable safety profile, than macular laser photocoagulation in the treatment of DME. • Major Eligibility Criteria • Best corrected E-ETDRS acuity >= 69 letters (20/40) • OCT central subfield thickness >= 250 microns • Enrollment (11/04-9/05) • Total enrolled: 113 subjects/137 eyes at 32 sites

17. Protocol F: An Observational Study of the Development of DME Following Scatter Laser Photocoagulation • Objective • To determine the incidence and extent of macular edema following PRP in eyes without macular edema and explore whether this varies according to the number of sittings included in the treatment regimen. • Major Eligibility Criteria • OCT central subfield thickness <=299 microns • Early PDR or severe NPDR for which investigator intends to perform full scatter photocoagulation in either 1 sitting or 4 sittings • Enrollment (9/05 – 4/07) • Total enrolled: 155 subjects at 27 sites

18. Protocol G: Subclinical Diabetic Macular Edema Study • Objective • To determine the incidence of progression of subclinical DME and to evaluate factors predictive of its presence and progression. • Major Eligibility Criteria • Best corrected E-ETDRS acuity >= 74 letters (20/32 or better) • Macular thickness judged to be normal on exam • OCT center point thickness 200-299 microns • Enrollment (11/05 – 4/07) • Total enrolled: 68 subjects/106 eyes at 19 sites

19. Protocol H: A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin) • Objective • To assess the dose and dose interval related effects of intravitreal administered bevacizumab on central retinal thickness and visual acuity in subjects with DME • Major Eligibility Criteria • Best corrected E-ETDRS acuity >= 24 letters (20/320 or better) • Center-involved DME present on clinical exam and OCT with central subfield thickness >= 275 microns • Enrollment (6/06-8/06) • Total enrolled: 121 subjects at 36 sites

20. Protocol K: The Course of Response to Focal Photocoagulation for Diabetic Macular Edema • Objective • To determine the course of changes in OCT measured macular thickness and visual acuity following a single session of focal photocoagulation for center-involved DME • Major Eligibility Criteria • DME involving the center of the macula (OCT central subfield thickness >250 microns • Investigator intends to treat the DME with focal photocoagulation • Enrollment (1/07 – 6/07) • Total enrolled: 128 subjects at 26 sites

21. Active Studies

22. Protocol I: Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination with Laser Photocoagulation for Diabetic Macular Edema • Objective • To evaluate the safety and efficacy of intravitreal anti-VEGF treatment in combination with focal laser photocoagulation, intravitreal anti-VEGF treatment alone, and intravitreal corticosteroids in combination with focal laser photocoagulation in eyes with center-involved DME • Major Eligibility Criteria • Diabetic macular edema involving the center of the macula (OCT central subfield thickness ≥ 250 microns) responsible for visual acuity of 20/32 or worse • Enrollment (Completed) • Total enrolled: 691 subjects/854 eyes at 52 sites

23. Protocol J: Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy • Objective • To determine whether intravitreal injection of an anti-VEGF drug or of a corticosteroid can reduce the risk of VA impairment that can occur following PRP and increase the chances of at least short-term VA improvement in eyes with center-involved macular edema that are undergoing PRP for severe NPDR or PDR • Major Eligibility Criteria • Diabetic macular edema involving the center of the macula (OCT central subfield thickness ≥250 microns) responsible for visual acuity of 20/32 or worse • PRP required for severe NPDR or PDR • Enrollment (Completed) • Total enrolled: 333 subjects/364 eyes at 48 sites

24. Protocol L: Evaluation of Visual Acuity Measurements in Eyes with Diabetic Macular Edema • Objective • To compare visual acuity results obtained based on the results of an autorefraction with the results of acuity testing based on the DRCR.net manual refraction protocol • To determine the reproducibility of E-ETDRS visual acuity measurements in subjects with center-involved DME at multiple centers • Major Eligibility Criteria • OCT central subfield thickness ≥250 microns • Visual acuity better than 20/400 (letter score ≥19) • Enrollment (Ongoing) • Total enrolled: 317 subjects at 26 sites (as of 11/4/09)

25. Protocol O: Comparison of Time Domain OCT and Spectral Domain OCT Retinal Thickness Measurement in Diabetic Macular Edema • Objective • To compare thickness measurements between Zeiss TD Stratus OCT and selected SD OCT machines (Zeiss Cirrus, Heidelberg Spectralis, and Topcon 3D-OCT), estimating a conversion factor between TD OCT and SD OCT • To assess and compare the reproducibility of the selected SD OCT machines utilizing their respective software analysis algorithms • Major Eligibility Criteria • Media clarity adequate for obtaining OCT images • DME in at least one eye (OCT central subfield thickness ≥250 microns) • Enrollment (Ongoing) • Total enrolled: 225 subjects at 20 sites (as of 11/4/09)

26. Protocol P: A Pilot Study in Individuals with Center-Involved DME Undergoing Cataract Surgery • Objective • To determine the feasibility of a randomized trial in eyes with center-involved DME prior to cataract surgery • To describe all eyes with respect to how cataract surgeons and DRCR.net investigators manage these cases at the time of surgery • To evaluate exacerbation of DME and VA at 16 weeks • Major Eligibility Criteria • Presence of cataract in study eye for which cataract surgery will be performed within 1-14 days after enrollment • Presence of DME in study eye (OCT central subfield thickness ≥250 microns) • VA light perception or better • Enrollment (Ongoing) • Total enrolled: 3 subjects/eyes at 3 sites (as of 11/4/09)

27. Protocol Q: An Observational Study in Individuals with Diabetic Retinopathy without Center-Involved DME Undergoing Cataract Surgery • Objective • To determine the incidence of progression to center-involved macular edema 16 weeks after cataract surgery in eyes with diabetic retinopathy and without definite center-involved DME • Major Eligibility Criteria • Presence of cataract in study eye for which cataract surgery is scheduled • Presence of microaneurysms or at least mild non-proliferative diabetic retinopathy (level 20 or higher) on clinical exam • No presence of center-involved DME in study eye (OCT central subfield thickness <250 microns) • VA light perception or better • Enrollment (Ongoing) • Total enrolled: 9 subjects/eyes at 5 sites (as of 11/4/09)

28. Upcoming Studies • An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (anticipated start January 2010) • Effect of Diabetes Education During Retina Examination on Diabetes Control (anticipated start 3rd quarter 2010) • An Evaluation of Topical NSAIDs on Progression on Non-Center Involved DME (anticipated start 2nd quarter 2010)